HALO Halozyme Therapeutics Earnings and EPS analysis

EPS in 2026 (TTM): $2.96

Last Report Period Date: Mar 31, 2026

As of June 2026, HALO's current EPS stands at $2.96, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $2.64, which marks a drop compared to its EPS of $3.5 in 2024. HALO reported an EPS of $1.27 for the quarterly report ending on Mar 31, 2026.

For 2025, Halozyme Therapeutics's EPS was $2.64, a drop of 24.6% from $3.5 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was $1.27, showing a 32.3% increase from the same quarter last year. For the twelve months ending March 2026, the EPS is $2.96. For the year 2024, the yearly earnings per share was $3.5, marking an increase of 64.3% from 2023.

Halozyme Therapeutics has registered an increase in EPS of 32.3% during the last 12 months (YoY, quarterly). Throughout the last three years, the company had an average EPS growth of 21.3% per year. Halozyme Therapeutics had an average annual EPS growth rate of 22.7% during the last 5 years.